Sort   by:  
 Page size 
UnknownSerum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients.
Not available
S-EPMC6073286 | biostudies-literature
UnknownEfficacy and outcome of molecular targeted therapies in elderly patients with hepatocellular carcinoma: Relative dose intensity associated with overall survival.
Not available
S-EPMC10757153 | biostudies-literature
UnknownEffect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells.
Not available
S-EPMC9468852 | biostudies-literature
UnknownEvaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells.
Not available
S-EPMC8657692 | biostudies-literature
UnknownAntitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines.
Not available
S-EPMC8835935 | biostudies-literature
UnknownIpragliflozin attenuates non-alcoholic steatohepatitis development in an animal model.
Not available
S-EPMC8863244 | biostudies-literature
UnknownGalectin‑9 suppresses the tumor growth of colon cancer in vitro and in vivo.
Not available
S-EPMC8072828 | biostudies-literature
UnknownPemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study.
Not available
S-EPMC10224826 | biostudies-literature
UnknownThe risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
Not available
S-EPMC5552231 | biostudies-literature
UnknownOptimal target blood pressure in elderly with septic shock (OPTPRESS) trial: study protocol for a randomized controlled trial.
Not available
S-EPMC9509562 | biostudies-literature
Sort   by:  
 Page size